Compugen Ltd. Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate
Published: Oct 16, 2013
TEL AVIV, Israel--(BUSINESS WIRE)--In a presentation tomorrow at the Autoimmune & Inflammation Leaders’ Forum in Boston, Massachusetts, Galit Rotman, PhD, Chief Scientist of Therapeutics at Compugen Ltd. (NASDAQ: CGEN), will disclose results from an animal model study in which CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, demonstrated potential to induce immune tolerance, a much desired goal for treatment of many immunological disorders. The presentation will also disclose recent positive results from a humanized animal model of psoriasis, further expanding the scope of autoimmune conditions potentially treatable by CGEN-15001.
Help employers find you! Check out all the jobs and post your resume.